Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Cadonilimab in HER2-expressing Gastric/GEJ Cancer
NCT06221748Phase 3Recruiting
- Sponsor
- RemeGen
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin, cadonilimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Started Feb 2024; status: recruiting.
02
Drugs
disitamab vedotincadonilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06221748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221748.